US Bancorp DE Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

US Bancorp DE trimmed its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 41.3% during the third quarter, HoldingsChannel.com reports. The fund owned 4,149 shares of the biopharmaceutical company’s stock after selling 2,916 shares during the period. US Bancorp DE’s holdings in Ultragenyx Pharmaceutical were worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. UMB Bank n.a. increased its stake in Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 352 shares during the period. Arizona State Retirement System grew its holdings in shares of Ultragenyx Pharmaceutical by 2.1% during the second quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 434 shares during the last quarter. ProShare Advisors LLC increased its position in Ultragenyx Pharmaceutical by 8.7% in the 1st quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company’s stock valued at $284,000 after acquiring an additional 486 shares during the period. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter valued at approximately $28,000. Finally, Sei Investments Co. lifted its position in Ultragenyx Pharmaceutical by 0.9% during the 1st quarter. Sei Investments Co. now owns 65,996 shares of the biopharmaceutical company’s stock worth $3,081,000 after acquiring an additional 616 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 1.8 %

Ultragenyx Pharmaceutical stock opened at $48.71 on Thursday. The stock has a 50-day moving average price of $54.64 and a 200 day moving average price of $48.30. Ultragenyx Pharmaceutical Inc. has a 52 week low of $36.51 and a 52 week high of $60.37. The stock has a market cap of $4.50 billion, a PE ratio of -7.53 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. During the same quarter in the previous year, the business earned ($2.23) earnings per share. The business’s revenue for the quarter was up 42.3% on a year-over-year basis. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.21 EPS for the current year.

Insider Activity

In related news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,556 shares of company stock worth $1,515,967 over the last 90 days. Company insiders own 5.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on RARE. Canaccord Genuity Group reissued a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Wells Fargo & Company boosted their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Barclays cut their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $86.69.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.